First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma Meeting Abstract
| Authors: | Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; Kelsen, D. P.; Ilson, D. H.; Solit, D. B.; Schultz, N.; Shah, P. M.; Capanu, M.; Hechtman, J. F. |
| Abstract Title: | First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 224s |
| Language: | English |
| ACCESSION: | WOS:000487345805200 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4011 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4011 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
